Century Therapeutics, Inc. (NASDAQ:IPSC) Given Average Rating of “Hold” by Analysts

Century Therapeutics, Inc. (NASDAQ:IPSC) has received a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $4.75.

Several equities research analysts recently weighed in on the company. Mizuho started coverage on Century Therapeutics in a report on Wednesday, May 27th. They issued an “outperform” rating and a $8.00 price objective for the company. Leerink Partners set a $2.00 target price on Century Therapeutics and gave the company a “market perform” rating in a report on Friday, March 13th. Zacks Research lowered Century Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a report on Monday, April 6th. Finally, TD Cowen started coverage on Century Therapeutics in a report on Wednesday, February 25th. They set a “buy” rating for the company.

Century Therapeutics Stock Performance

Shares of IPSC opened at $2.21 on Wednesday. The business has a 50-day moving average of $2.27 and a 200 day moving average of $1.85. Century Therapeutics has a fifty-two week low of $0.44 and a fifty-two week high of $3.04. The firm has a market cap of $398.57 million, a P/E ratio of -1.94 and a beta of 1.56.

Century Therapeutics (NASDAQ:IPSC) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.04. As a group, research analysts predict that Century Therapeutics will post -0.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Century Therapeutics news, insider Gregory Russotti sold 10,076 shares of Century Therapeutics stock in a transaction dated Thursday, March 12th. The stock was sold at an average price of $2.55, for a total transaction of $25,693.80. Following the completion of the transaction, the insider owned 515,427 shares of the company’s stock, valued at $1,314,338.85. The trade was a 1.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last ninety days, insiders sold 18,156 shares of company stock worth $45,902. 2.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Prudential Financial Inc. purchased a new position in Century Therapeutics during the 2nd quarter valued at about $25,000. Bank of New York Mellon Corp bought a new stake in shares of Century Therapeutics during the 1st quarter valued at about $29,000. Qube Research & Technologies Ltd bought a new stake in shares of Century Therapeutics during the 2nd quarter valued at about $38,000. Quadrant Private Wealth Management LLC boosted its position in shares of Century Therapeutics by 31.0% during the 1st quarter. Quadrant Private Wealth Management LLC now owns 20,022 shares of the company’s stock valued at $45,000 after acquiring an additional 4,736 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Century Therapeutics during the 2nd quarter valued at about $51,000. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Company Profile

Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays.

The company’s proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates.